« Return to News | Clinical Intelligence

Neovasc's COSIRA clinical trial protocol to be published in peer-reviewed journal

Thursday, February 28, 2013 02:27 PM

Vancouver-based Neovasc said the clinical protocol for its COSIRA (coronary sinus reducer for treatment of refractory angina) trial has been published in the peer-reviewed journal Trials. COSIRA is a double-blind, randomized, multi-center trial further assessing the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.  The COSIRA trial is currently enrolling patients in the U.K., Europe and  Canada. 

"COSIRA was designed as a rigorous, sham-controlled study to provide  definitive evidence of the efficacy of the Reducer device, and we are  pleased that the protocol is being recognized as noteworthy by the  clinical research community," said Shmuel Banai, M.D., chief medical officer of Neovasc.  "We are on target for completion of patient  enrollment in the second quarter of 2013, with six-month follow-up data  from all patients expected to be available around year's end."

The Reducer has received a CE mark designation in Europe for treatment of refractory angina.  Neovasc is also following Reducer  patients in two open-label Registries being conducted in Europe and  Israel.

Neovasc CEO Alexei Marko said, "Patient outcome data from our pilot studies and Registry patients enrolled to date has been very promising, and we look forward to reporting the results of the COSIRA study in the coming months." 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.